Clinical Trial Update: Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors [EARLY_Phase 1]

View source ↗

Summary

An early-phase, open-label, single-arm imaging and dosimetry study of the radiolabeled agent I-124 PGN650 in patients with advanced solid tumors; the trial stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• I-124 PGN650 (PGN650)

Snippet

Sponsor: Peregrine Pharmaceuticals | Conditions: Malignant Solid Tumor | EARLY_Phase 1 | Status: TERMINATED